Janet Wei

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3023334/publications.pdf

Version: 2024-02-01

394421 214800 2,374 61 19 47 h-index citations g-index papers 62 62 62 2077 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Ischemia and No Obstructive Coronary Artery Disease (INOCA). Circulation, 2017, 135, 1075-1092.	1.6	527
2	Cardiac Magnetic Resonance Myocardial Perfusion Reserve Index Is Reduced in Women With Coronary Microvascular Dysfunction. Circulation: Cardiovascular Imaging, 2015, 8, .	2.6	184
3	Ranolazine Improves Angina in Women With Evidence of Myocardial Ischemia But No Obstructive Coronary Artery Disease. JACC: Cardiovascular Imaging, 2011, 4, 514-522.	5.3	180
4	Coronary Optical Coherence Tomography and Cardiac Magnetic Resonance Imaging to Determine Underlying Causes of Myocardial Infarction With Nonobstructive Coronary Arteries in Women. Circulation, 2021, 143, 624-640.	1.6	180
5	Safety of Coronary Reactivity Testing in Women With No Obstructive Coronary Artery Disease. JACC: Cardiovascular Interventions, 2012, 5, 646-653.	2.9	177
6	A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. European Heart Journal, 2016, 37, 1504-1513.	2.2	152
7	Impact of Abnormal Coronary Reactivity on Long-Term Clinical Outcomes inÂWomen. Journal of the American College of Cardiology, 2019, 73, 684-693.	2.8	152
8	Ischemia and No Obstructive Coronary Artery Disease (INOCA): What Is the Risk?. Journal of the American Heart Association, 2018, 7, e008868.	3.7	124
9	Coronary Microvascular Dysfunction ― Epidemiology, Pathogenesis, Prognosis, Diagnosis, Risk Factors and Therapy ―. Circulation Journal, 2017, 81, 3-11.	1.6	73
10	Diastolic Dysfunction in Women With Signs and Symptoms of Ischemia in the Absence of Obstructive Coronary Artery Disease. Circulation: Cardiovascular Imaging, 2014, 7, 510-516.	2.6	55
11	Sex-based differences in quality of care and outcomes in a health system using a standardized STEMI protocol. American Heart Journal, 2017, 191, 30-36.	2.7	53
12	Coronary Atherosclerosis T1-Weighed Characterization With Integrated Anatomical Reference. JACC: Cardiovascular Imaging, 2017, 10, 637-648.	5.3	43
13	Coronary Microvascular Dysfunction Causing Cardiac Ischemia in Women. JAMA - Journal of the American Medical Association, 2019, 322, 2334.	7.4	31
14	Coronary Arterial Function and Disease in Women With No Obstructive Coronary Arteries. Circulation Research, 2022, 130, 529-551.	4.5	29
15	Heart failure hospitalization in women with signs and symptoms of ischemia: A report from the women's ischemia syndrome evaluation study. International Journal of Cardiology, 2016, 223, 936-939.	1.7	28
16	Myocardial Scar Is Prevalent and Associated With Subclinical Myocardial Dysfunction in Women With Suspected Ischemia But No Obstructive Coronary Artery Disease. Circulation, 2018, 137, 874-876.	1.6	23
17	Myocardial tissue deformation is reduced in subjects with coronary microvascular dysfunction but not rescued by treatment with ranolazine. Clinical Cardiology, 2017, 40, 300-306.	1.8	22
18	Prevalence of Coronary Endothelial and Microvascular Dysfunction in Women with Symptoms of Ischemia and No Obstructive Coronary Artery Disease Is Confirmed by a New Cohort: The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation–Coronary Vascular Dysfunction (WISE-CVD). Journal of Interventional Cardiology, 2019, 2019, 1-8.	1.2	22

#	Article	IF	Citations
19	Microvascular Dysfunction as a Systemic Disease: A Review of the Evidence. American Journal of Medicine, 2022, 135, 1059-1068.	1.5	22
20	Fiveâ€Year Followâ€Up of Coronary Microvascular Dysfunction and Coronary Artery Disease in Systemic Lupus Erythematosus: Results From a Communityâ€Based Lupus Cohort. Arthritis Care and Research, 2020, 72, 882-887.	3.4	21
21	Cardiovascular magnetic resonance in autoimmune rheumatic diseases: a clinical consensus document by the European Association of Cardiovascular Imaging. European Heart Journal Cardiovascular Imaging, 2022, 23, e308-e322.	1.2	21
22	Predicted Versus Observed Major Adverse Cardiac Event Risk in Women With Evidence of Ischemia and No Obstructive Coronary Artery Disease: A Report From WISE (Women's Ischemia Syndrome) Tj ETQq0 0 0 rgBT	/Osværlock	10.8f 50 617
23	Autologous CD34+ Stem Cell Therapy Increases Coronary Flow Reserve and Reduces Angina in Patients With Coronary Microvascular Dysfunction. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121010802.	3.9	16
24	Coronary microvascular dysfunction: Considerations for diagnosis and treatment. Cleveland Clinic Journal of Medicine, 2021, 88, 561-571.	1.3	15
25	Diastolic dysfunction measured by cardiac magnetic resonance imaging in women with signs and symptoms of ischemia but no obstructive coronary artery disease. International Journal of Cardiology, 2016, 220, 775-780.	1.7	14
26	Resting coronary velocity and myocardial performance in women with impaired coronary flow reserve: Results from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD) study. International Journal of Cardiology, 2020, 309, 19-22.	1.7	12
27	Contemporary clinical updates on the prevention of future cardiovascular disease in women who experience adverse pregnancy outcomes. Clinical Cardiology, 2020, 43, 553-559.	1.8	12
28	Inverse association of MRI-derived native myocardial T1 and perfusion reserve index in women with evidence of ischemia and no obstructive CAD: A pilot study. International Journal of Cardiology, 2018, 270, 48-53.	1.7	11
29	Left ventricular concentric remodelling and functional impairment in women with ischaemia with no obstructive coronary artery disease and intermediate coronary flow reserve: a report from the WISE-CVD study. European Heart Journal Cardiovascular Imaging, 2019, 20, 875-882.	1.2	11
30	Adverse Pregnancy Outcomes Are Associated with Reduced Coronary Flow Reserve in Women With Signs and Symptoms of Ischemia Without Obstructive Coronary Artery Disease: A Report from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction Study. Journal of Women's Health, 2020, 29, 487-492.	3.3	11
31	Ambulatory and silent myocardial ischemia in women with coronary microvascular dysfunction: Results from the Cardiac Autonomic Nervous System study (CANS). International Journal of Cardiology, 2020, 316, 1-6.	1.7	11
32	Coronary endothelial dysfunction appears to be a manifestation of a systemic process: A report from the Women's Ischemia Syndrome Evaluation – Coronary Vascular Dysfunction (WISE-CVD) study. PLoS ONE, 2021, 16, e0257184.	2.5	11
33	Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial. JMIR Research Protocols, 2017, 6, e255.	1.0	11
34	Angina relates to coronary flow in women with ischemia and no obstructive coronary artery disease. International Journal of Cardiology, 2021, 333, 35-39.	1.7	10
35	Left atrial stiffness in women with ischemia and no obstructive coronary artery disease: Novel insight from left atrial feature tracking. Clinical Cardiology, 2020, 43, 986-992.	1.8	9
36	Quantification of myocardial blood flow using non-electrocardiogram-triggered MRI with three-slice coverage. Magnetic Resonance in Medicine, 2016, 75, 2112-2120.	3.0	7

#	Article	IF	CITATIONS
37	First-pass myocardial perfusion MRI with reduced subendocardial dark-rim artifact using optimized Cartesian sampling. Journal of Magnetic Resonance Imaging, 2017, 45, 542-555.	3.4	7
38	Coronary Microvascular Dysfunction in Patients With Systemic Lupus Erythematosus and Chest Pain. Frontiers in Cardiovascular Medicine, 2022, 9, 867155.	2.4	7
39	Left ventricular mass and myocardial scarring in women with hypertensive disorders of pregnancy. Open Heart, 2020, 7, e001273.	2.3	6
40	Even "WISE-R?â€â€"an Update on the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation. Current Atherosclerosis Reports, 2020, 22, 35.	4.8	6
41	Body weight and physical fitness in women with ischaemic heart disease: does physical fitness contribute to our understanding of the obesity paradox in women?. European Journal of Preventive Cardiology, 2022, 29, 1608-1614.	1.8	6
42	Are we any WISER yet? Progress and contemporary need for smart trials to include women in coronary artery disease trials. Contemporary Clinical Trials, 2022, 117, 106762.	1.8	6
43	Not typical angina and mortality in women with obstructive coronary artery disease: Results from the Women's Ischemic Syndrome Evaluation study (WISE). IJC Heart and Vasculature, 2020, 27, 100502.	1.1	5
44	Challenging Statin Pleiotropy: Preeclampsia. Circulation, 2021, 144, 680-683.	1.6	5
45	Gender equity in <scp>STEMI</scp> : Not so simple!. Catheterization and Cardiovascular Interventions, 2015, 85, 369-370.	1.7	4
46	Vascular Function and Serum Lipids in Women with Spontaneous Preterm Delivery and Term Controls. Journal of Women's Health, 2019, 28, 1522-1528.	3.3	4
47	The Clinical Spectrum of Myocardial Infarction and Ischemia With Nonobstructive Coronary Arteries in Women. JACC: Cardiovascular Imaging, 2021, 14, 1053-1062.	5.3	4
48	Maladaptive left ventricular remodeling in women: An analysis from the Women's Ischemia Syndrome Evaluationâ€"Coronary Vascular Dysfunction study. International Journal of Cardiology, 2018, 268, 230-235.	1.7	3
49	Sex differences and the left ventricle: morphology matters. European Heart Journal Cardiovascular Imaging, 2020, 21, 991-993.	1.2	3
50	Diagnosis of an aortic valvular lesion. Heart, 2015, 101, 719-719.	2.9	2
51	Vascular Aging Is Accelerated in Flight Attendants With Occupational Secondhand Smoke Exposure. Journal of Occupational and Environmental Medicine, 2019, 61, 197-202.	1.7	2
52	Current Perspective on Menopause Hormone Therapy and Cardiovascular Risk. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.9	2
53	Association of coronary microvascular dysfunction and cardiac bridge integrator 1, a cardiomyocyte dysfunction biomarker. Clinical Cardiology, 2021, 44, 1586-1593.	1.8	2
54	Cardiovascular and pregnancy outcomes in women with coronary microvascular dysfunction: a case series. European Heart Journal - Case Reports, 2019, 3, .	0.6	1

#	Article	IF	Citations
55	Sex-based differences in remote monitoring of biometric, psychometric and biomarker indices in stable ischemic heart disease. Biology of Sex Differences, 2022, 13, 15.	4.1	1
56	Editorial commentary: Coronary plaque burden regression and high-risk plaque reversal: Potential biomarkers for secondary prevention?. Trends in Cardiovascular Medicine, 2016, 26, 162-164.	4.9	0
57	Relationship between coronary function testing and migraine: results from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction project. , 2021, 5, .		O
58	Abstract 16281: Non-calcified Coronary Plaque Burden is Related to Epicardial Adipose Tissue and Peri-coronary Adipose Tissue Attenuation in Heart Failure With Preserved Ejection Fraction. Circulation, 2020, 142, .	1.6	O
59	Subclinical hepatic fibrosis is associated with coronary microvascular dysfunction by myocardial perfusion reserve index: a retrospective cohort study. International Journal of Cardiovascular Imaging, 2022, , 1.	1.5	O
60	Abstract 10596: Telephone-Based Stress Management in Women with Myocardial Infarction: Findings from the Go Red for Women Strategically Focused Research Network. Circulation, 2021, 144, .	1.6	0
61	Mortality Risk in Takotsubo Syndrome Versus Myocarditis. Journal of the American Heart Association, 2022, 11, .	3.7	0